Back to News
Market Impact: 0.2
PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data
Source: marketbeat.com
Healthcare & BiotechCompany Fundamentals
PolyPid is approaching a November 28 PDUFA date for D-PLEX100, its lead candidate to prevent surgical site infections in colorectal surgery patients. CEO Dikla Czaczkes Akselbrad disclosed the timing at the Lytham Partners Fall 2026 Investor Conference; the article reports no regulatory decision or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
PYPD0.15
More News
- ‘Unwelcome and unsafe’: Why Japanese companies are retreating from China at a record pace
- Sen. Mitch McConnell closed a loophole in a hemp law he championed. Now a $28 billion THC industry that gets people high is fighting for survival
- Can America Break China’s Grip on Rare Earths?
- They survived World War II and lost decades, but not 2026. Japan's century-old businesses are disappearing at a record pace
- Tom Cruise suffers one of the worst movie debuts of his career. Reviews were so bad Warner Bros. ran ‘decide for yourself’ ads
- Schneider Electric close to $20 bln deal of U.S. software maker PTC - report